Your session is about to expire
← Back to Search
EGCG 300 mg for Idiopathic Pulmonary Fibrosis
Study Summary
"This trial aims to see if a specific type of imaging test using a collagen-targeted PET probe can help understand the effects of a drug called EGCG and determine the right dosage to use."
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of individuals being admitted into this research investigation?
"Affirmative. The information available on clinicaltrials.gov highlights that this investigation is currently seeking suitable candidates. Initially shared on February 7th, 2024, the trial details were last revised on February 9th, 2024. A total of 22 participants are being sought from a single designated site."
Are potential participants currently able to apply for enrollment in this trial?
"Affirmative. Information on clinicaltrials.gov states that this medical investigation is presently seeking suitable participants. The initial posting date was 2/7/2024, and the most recent revision occurred on 2/9/2024. This study aims to enroll 22 individuals at a single site."
Is the research study open to participants who are younger than 18 years old?
"Potential participants eligible for this research must be aged between 40 and 85 years. There are no ongoing studies for individuals under 18, but there are 104 trials catering to those above the age of 65."
Would it be possible for me to participate in this medical study?
"Individuals aged between 40 and 85 with a diagnosis of idiopathic pulmonary fibrosis are eligible to participate in this study, which aims to enroll approximately 22 individuals."
What are the potential risks associated with consuming EGCG at a dosage of 300 mg for individuals?
"Our team at Power has evaluated the safety of EGCG 300 mg to be a score of 1 on our scale. This assessment is based on this being a Phase 1 trial with limited existing data supporting both its effectiveness and safety profiles."
Share this study with friends
Copy Link
Messenger